Breast cancer risk factors and HER2 over-expression in tumors.
Few epidemiologic studies have investigated the potential role of HER2 in the etiology of breast cancer. We conducted a case-case study of 156 women with incident, invasive ductal carcinoma. Multivariate unconditional logistic regression was used to estimate the odds ratios for a HER2 positive tumor in relation to known and putative risk factors of breast cancer. HER2 status was detected by immunohistochemistry on archival tissue. HER2 positive breast cancers tended to be larger and were less likely to express estrogen receptors, and the incidence rate was higher in patients less than 40 years old. We observed an association between a self-reported history of benign breast disease and the occurrence of HER2 positive breast cancer (OR, 2.1;95% CI, 1.1-4.1). We did not detect associations between HER2 over-expression and family history of breast cancer, parity, late age at first birth, ever having breast fed an infant, or oral contraceptive use. Our findings merit consideration in light of recent evidence of HER2 amplification or over-expression in benign breast disease. Should the link to breast cancer be established, HER2 positive benign breast disease could potentially serve as an early marker for preventive intervention.
Swede
H
H
Department of Cancer Prevention, Epidemiology and Biostatistics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Moysich
K B
KB
Freudenheim
J L
JL
Quirk
J T
JT
Muti
P C
PC
Hurd
T C
TC
Edge
S B
SB
Winston
J S
JS
Michalek
A M
AM
D000328:Adult; D001943:Breast Neoplasms / Q000209:etiology* / Q000378:metabolism*; D003276:Contraceptives, Oral; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008572:Menarche; D008593:Menopause; D008597:Menstrual Cycle; D010298:Parity; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D012307:Risk Factors
D003276:Contraceptives, Oral; D018719:Erb-b2 Receptor Tyrosine Kinases